Evidence map›Paper›PMID 36881873›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2023

A Real-Time Image-Based Efferocytosis Assay for the Discovery of Functionally Inhibitory Anti-MerTK Antibodies.

Daniel D Bravo, Yongchang Shi, Allison Sheu, Wei-Ching Liang, WeiYu Lin, Yan Wu, Minhong Yan, Jianyong Wang

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Frontiers in immunology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Daniel D BravoDepartment of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA.
Yongchang ShiDepartment of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA.ORCID 0000-0001-5112-0334
Allison SheuDepartment of Molecular and Cellular Biology, University of California, Berkeley, Berkeley, CA.ORCID 0000-0003-2271-5042
Wei-Ching LiangDepartment of Antibody Engineering, Genentech, Inc., South San Francisco, CA.
WeiYu LinDepartment of Antibody Engineering, Genentech, Inc., South San Francisco, CA.
Yan WuDepartment of Antibody Engineering, Genentech, Inc., South San Francisco, CA.
Minhong YanDepartment of Molecular Oncology, Genentech, Inc., South San Francisco, CA.
Jianyong WangDepartment of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA.ORCID 0000-0002-1221-2698
Biochemical Society · GBResearch & Diagnostic Antibodies (United States) · USMolecular Oncology (United States) · USUniversity of California, Berkeley · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efferocytosis is a phagocytic process by which apoptotic cells are cleared by professional and nonprofessional phagocytic cells. In tumors, efferocytosis of apoptotic cancer cells by tumor-associated macrophages prevents Ag presentation and suppresses the host immune response against the tumor. Therefore, reactivating the immune response by blockade of tumor-associated macrophage-mediated efferocytosis is an attractive strategy for cancer immunotherapy. Even though several methods have been developed to monitor efferocytosis, an automated and high-throughput quantitative assay should offer highly desirable advantages for drug discovery. In this study, we describe a real-time efferocytosis assay with an imaging system for live-cell analysis. Using this assay, we successfully discovered potent anti-MerTK Abs that block tumor-associated macrophage-mediated efferocytosis in mice. Furthermore, we used primary human and cynomolgus monkey macrophages to identify and characterize anti-MerTK Abs for potential clinical development. By studying the phagocytic activities of different types of macrophages, we demonstrated that our efferocytosis assay is robust for screening and characterization of drug candidates that inhibit unwanted efferocytosis. Moreover, our assay is also applicable to investigating the kinetics and molecular mechanisms of efferocytosis/phagocytosis.

Indexed as

ApoptosisNeoplasmsAnimalsc-Mer Tyrosine KinaseHumansMacaca fascicularisMacrophagesMicePhagocytosisc-Mer Tyrosine Kinase

Identifiers

PMID36881873
PMCPMC10067786
OpenAlexW4323350413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.